Suzhou's Innovent Biologics: Interview With CEO Michael Yu

In January, Innovent Biologics, a Suzhou biopharma formed in 2011, made a dramatic statement by announcing a large $100 million C series funding. Innovent is committed to producing affordably priced, high quality biologic drugs for China and global markets. The company is developing a portfolio of ten biosimilar and novel biologic drugs, in addition to offering biologic CMO services to global pharmas. Michael Yu, the Co-Founder, President and CEO of Innovent, recently spoke in an exclusive interview with partneringNEWS™, a publication of ChinaBio®'s partner EBD Group.

Help employers find you! Check out all the jobs and post your resume.